Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2025 · 10-Q
Revenue$21.93M$21.93Mno prior Q1 2024 on file Net Income-$2.20M-$2.20MN/M vs Q1 2024 EPS Diluted-$0.12-$0.12N/M vs Q1 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$3,864,000+82.4% Free Cash Flowderived$3,837,000+83.9% Margins · derivedGross margin60.9%
Operating margin-9.6%
Net margin-10.0%
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end